Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies

Qingfu Dong; Haolin Bao; Jiangang Wang; Wujiang Shi; Xinlei Zou; Jialin Sheng; Jianjun Gao; Canghai Guan; Haoming Xia; Jinglin Li; Pengcheng Kang; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yi Xu; Yunfu Cui; Xiangyu Zhong

doi:10.3389/fmed.2023.1120621

Frontiers in Medicine (Apr 2023)

Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies

Qingfu Dong,
Haolin Bao,
Jiangang Wang,
Wujiang Shi,
Xinlei Zou,
Jialin Sheng,
Jianjun Gao,
Canghai Guan,
Haoming Xia,
Jinglin Li,
Pengcheng Kang,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yi Xu,
Yunfu Cui,
Xiangyu Zhong

Affiliations

Qingfu Dong: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Haolin Bao: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Jiangang Wang: Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China
Wujiang Shi: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Xinlei Zou: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Jialin Sheng: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Jianjun Gao: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Canghai Guan: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Haoming Xia: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Jinglin Li: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Pengcheng Kang: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Yi Xu: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Yi Xu: Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
Yi Xu: Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen, Fujian, China
Yi Xu: Jiangsu Province Engineering Research Center of Tumor Targeted Nano Diagnostic and Therapeutic Materials, Yancheng Teachers University, Yancheng, Jiangsu, China
Yi Xu: Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Hangzhou, Zhejiang, China
Yi Xu: Key Laboratory of Gastrointestinal Cancer, Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China
Yi Xu: State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, China
Yi Xu: Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Yi Xu: 0Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Department of Pharmacy, Changxing People's Hospital, Changxing, Zhejiang, China
Yunfu Cui: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Xiangyu Zhong: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China

DOI: https://doi.org/10.3389/fmed.2023.1120621
Journal volume & issue: Vol. 10

Abstract

Read online

In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the stage of liver fibrosis is associated with an increased risk of severe liver-related and cardiovascular events and is the strongest predictor of mortality in MAFLD patients. More and more people believe that MAFLD is a multifactorial disease with multiple pathways are involved in promoting the progression of liver fibrosis. Numerous drug targets and drugs have been explored for various anti-fibrosis pathways. The treatment of single medicines is brutal to obtain satisfactory results, so the strategies of multi-drug combination therapies have attracted increasing attention. In this review, we discuss the mechanism of MAFLD-related liver fibrosis and its regression, summarize the current intervention and treatment methods for this disease, and focus on the analysis of drug combination strategies for MAFLD and its subsequent liver fibrosis in recent years to explore safer and more effective multi-drug combination therapy strategies.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords